These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35631358)

  • 21. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
    Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
    ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mechanistic and kinetic study of the beta-lactone hydrolysis of Salinosporamide A (NPI-0052), a novel proteasome inhibitor.
    Denora N; Potts BC; Stella VJ
    J Pharm Sci; 2007 Aug; 96(8):2037-47. PubMed ID: 17554770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors.
    Lodola A; Capoferri L; Rivara S; Tarzia G; Piomelli D; Mulholland A; Mor M
    J Med Chem; 2013 Mar; 56(6):2500-12. PubMed ID: 23425199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of binding modes and affinities of 4-substituted-2,3,5,6-tetrafluorobenzenesulfonamide inhibitors to the carbonic anhydrase receptor by docking and ONIOM calculations.
    Samanta PN; Das KK
    J Mol Graph Model; 2016 Jan; 63():38-48. PubMed ID: 26619075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating QM/MM Free Energy Surfaces for Ranking Cysteine Protease Covalent Inhibitors.
    da Costa CHS; Bonatto V; Dos Santos AM; Lameira J; Leitão A; Montanari CA
    J Chem Inf Model; 2020 Feb; 60(2):880-889. PubMed ID: 31944110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations.
    Lodola A; Callegari D; Scalvini L; Rivara S; Mor M
    Methods Mol Biol; 2020; 2114():307-337. PubMed ID: 32016901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macyranones: Structure, Biosynthesis, and Binding Mode of an Unprecedented Epoxyketone that Targets the 20S Proteasome.
    Keller L; Plaza A; Dubiella C; Groll M; Kaiser M; Müller R
    J Am Chem Soc; 2015 Jul; 137(25):8121-30. PubMed ID: 26050527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study.
    Zhang S; Shi Y; Jin H; Liu Z; Zhang L; Zhang L
    J Mol Model; 2009 Dec; 15(12):1481-90. PubMed ID: 19440739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (-)-Homosalinosporamide A and Its Mode of Proteasome Inhibition: An X-ray Crystallographic Study.
    Groll M; Nguyen H; Vellalath S; Romo D
    Mar Drugs; 2018 Jul; 16(7):. PubMed ID: 30029468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantum Mechanics/Molecular Mechanics Studies of the Mechanism of Cysteine Proteases Inhibition by Dipeptidyl Nitroalkenes.
    Arafet K; González FV; Moliner V
    Chemistry; 2020 Feb; 26(9):2002-2012. PubMed ID: 31692123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ONIOM calculations on serotonin degradation by monoamine oxidase B: insight into the oxidation mechanism and covalent reversible inhibition.
    Cakir K; Erdem SS; Atalay VE
    Org Biomol Chem; 2016 Oct; 14(39):9239-9252. PubMed ID: 27605388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic Investigation of Lysine-Targeted Covalent Inhibition of PI3Kδ via ONIOM QM:QM Computations.
    Fındık V; Varınca Gerçik BT; Sinek Ö; Erdem SS; Ruiz-López MF
    J Chem Inf Model; 2022 Dec; 62(24):6775-6787. PubMed ID: 35980989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
    Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fundamental reaction pathway and free energy profile of proteasome inhibition by syringolin A (SylA).
    Wei D; Tang M; Zhan CG
    Org Biomol Chem; 2015 Jun; 13(24):6857-65. PubMed ID: 26018983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
    Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90.
    Goasduff T; Cederbaum AI
    Arch Biochem Biophys; 2000 Jul; 379(2):321-30. PubMed ID: 10898951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reaction mechanism of Ru(II) piano-stool complexes: umbrella sampling QM/MM MD study.
    Futera Z; Burda JV
    J Comput Chem; 2014 Jul; 35(19):1446-56. PubMed ID: 24865949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10.
    Schmidtke G; Schregle R; Alvarez G; Huber EM; Groettrup M
    Mol Immunol; 2019 Sep; 113():22-30. PubMed ID: 29208314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantifying free energy profiles of proton transfer reactions in solution and proteins by using a diabatic FDFT mapping.
    Xiang Y; Warshel A
    J Phys Chem B; 2008 Jan; 112(3):1007-15. PubMed ID: 18166038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome.
    Hasinoff BB
    Arch Biochem Biophys; 2018 Feb; 639():52-58. PubMed ID: 29305052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.